← Back to Clinical Trials
Recruiting Phase 1 NCT07264270

NCT07264270 Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07264270
Status Recruiting
Phase Phase 1
Sponsor Consano Bio
Condition Lumbosacral Radicular Pain
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2025-12-03
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
C-1101Placebo: Sterile Saline

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.

This trial targets 24 participants in total. It began in 2025-12-03 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of C-1101 administered as a single dose, transforaminal epidural injection compared to sterile saline

Eligibility Criteria

Inclusion Criteria: * Diagnosis of painful LSR (sciatica) radiating to or below the knee, with an inadequate response to conservative care * Body mass index \< 40 kg/m2. Exclusion Criteria: * Presence of clinically significant disease or any other painful condition that may interfere with assessments. * Any condition that currently requires blood or platelet transfusions. * Diagnosed with schizophrenia, bipolar disorder, or major depressive disorder. * Increased risk of bleeding or is taking anticoagulants or platelet aggregation inhibitors. * History or presence of autonomic neuropathy, diabetic neuropathy, or other peripheral neuropathies. * History of myocardial infarction within the last 6 months or congestive heart failure. * The presence of an active malignancy or tumor. * Have undergone a surgical procedure for back pain. * Recent use of immunosuppressants, oral steroids, or intravenous steroids.

Contact & Investigator

Central Contact

Senior Director, Clinical Development Operations

✉ ClinicalDev@consanobio.com

📞 U.S.:+1-508-492-0599

Principal Investigator

Consano Chief Medical Officer

STUDY DIRECTOR

Consano Bio

Frequently Asked Questions

Who can join the NCT07264270 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Lumbosacral Radicular Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07264270 trial and what does that mean for participants?

Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.

Is NCT07264270 currently recruiting?

Yes, NCT07264270 is actively recruiting participants. Contact the research team at ClinicalDev@consanobio.com for enrollment information.

Where is the NCT07264270 trial being conducted?

This trial is being conducted at Fernandina Beach, United States, Winston-Salem, United States, Richmond, United States, Broadmeadow, Australia and 2 additional locations.

Who is sponsoring the NCT07264270 clinical trial?

NCT07264270 is sponsored by Consano Bio. The principal investigator is Consano Chief Medical Officer at Consano Bio. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology